New data show no adverse outcomes in infants exposed to the flu vaccine in utero.
A crowdsourcing appeal for creative solutions for safely reopening the University of North Carolina at Chapel Hill amid the COVID-19 pandemic in fall 2020 netted 82 submissions from 110 students, faculty, and staff, according to a qualitative study today in JAMA Network Open.
Infants born to women with COVID-19 have a low chance of contracting the disease from their mothers and having complications, according to a study published yesterday in JAMA.
The World Health Organization (WHO) today announced that its influenza vaccine strain selection committee has made its recommendations for the Northern Hemisphere's 2021-22 flu season, which swaps out the two influenza A strains for both the egg-based and cell-based or recombinant vaccines.
Telemedicine visits in Brazil performed under rigorous adherence to antibiotic stewardship guidelines were associated with appropriate antibiotic prescribing for patients with low-risk conditions, Brazilian and Australian researchers reported yesterday in the International Journal of Infectious Diseases.
COVID-19 infection rates in US Immigration and Customs Enforcement (ICE) detention centers are higher than those in the general population and eclipse those of surrounding communities, according to a research letter published today in JAMA Network Open.
Truly revolutionary flu vaccines and equitable distribution are key goals.
Overcoming obstacles to better flu vaccines requires collaboration through innovative approaches on a broad scale.
Pregnant women with COVID-19 are more likely to experience complications such as heart attacks or blood clots, though the absolute increased risk is small, according to a JAMA Internal Medicine research letter today.
These findings highlight the need for risk mitigations, the authors write, adding that pregnant women should also be included in COVID-19 vaccine and treatment trials.
Interviews with policymakers and antimicrobial resistance (AMR) experts from 13 countries indicate broad support for financial incentives to boost antibiotic development, despite uncertainty over which incentives are appropriate and how much they'll cost, according to a policy brief released yesterday by the European Union Joint Action Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI) and the Glob